Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 14.06
(3.23%)
CNY 14.06
(3.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.49 Billion CNY | 7.76% |
| 2022 | 2.31 Billion CNY | 2.47% |
| 2021 | 2.25 Billion CNY | -3.59% |
| 2020 | 2.34 Billion CNY | -5.99% |
| 2019 | 2.49 Billion CNY | 9.83% |
| 2018 | 2.26 Billion CNY | 60.53% |
| 2017 | 1.41 Billion CNY | 65.78% |
| 2016 | 852.42 Million CNY | -6.19% |
| 2015 | 908.68 Million CNY | 126.43% |
| 2014 | 401.31 Million CNY | 144.0% |
| 2013 | 164.47 Million CNY | 53.11% |
| 2012 | 107.42 Million CNY | 80.36% |
| 2011 | 59.55 Million CNY | 84.4% |
| 2010 | 32.29 Million CNY | -40.99% |
| 2009 | 54.73 Million CNY | 46.64% |
| 2008 | 37.32 Million CNY | 291.21% |
| 2007 | 9.54 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.38 Billion CNY | 10.72% |
| 2024 Q1 | 2.21 Billion CNY | -11.13% |
| 2024 Q2 | 2.15 Billion CNY | -2.74% |
| 2023 Q2 | 2.2 Billion CNY | -2.05% |
| 2023 Q3 | 2.14 Billion CNY | -3.03% |
| 2023 FY | 2.49 Billion CNY | 7.76% |
| 2023 Q4 | 2.49 Billion CNY | 16.42% |
| 2023 Q1 | 2.25 Billion CNY | -2.54% |
| 2022 Q1 | 2.19 Billion CNY | -2.92% |
| 2022 Q4 | 2.31 Billion CNY | 5.49% |
| 2022 Q2 | 2.21 Billion CNY | 1.12% |
| 2022 FY | 2.31 Billion CNY | 2.47% |
| 2022 Q3 | 2.19 Billion CNY | -1.05% |
| 2021 Q3 | 2.24 Billion CNY | 1.48% |
| 2021 Q1 | 2.59 Billion CNY | 10.77% |
| 2021 Q2 | 2.21 Billion CNY | -14.72% |
| 2021 FY | 2.25 Billion CNY | -3.59% |
| 2021 Q4 | 2.25 Billion CNY | 0.58% |
| 2020 Q4 | 2.34 Billion CNY | -3.02% |
| 2020 FY | 2.34 Billion CNY | -5.99% |
| 2020 Q1 | 2.43 Billion CNY | -2.22% |
| 2020 Q2 | 2.38 Billion CNY | -2.28% |
| 2020 Q3 | 2.41 Billion CNY | 1.45% |
| 2019 FY | 2.49 Billion CNY | 9.83% |
| 2019 Q1 | 2.24 Billion CNY | -1.01% |
| 2019 Q2 | 2.55 Billion CNY | 13.58% |
| 2019 Q3 | 2.57 Billion CNY | 0.87% |
| 2019 Q4 | 2.49 Billion CNY | -3.17% |
| 2018 Q4 | 2.26 Billion CNY | 23.62% |
| 2018 FY | 2.26 Billion CNY | 60.53% |
| 2018 Q3 | 1.83 Billion CNY | 8.51% |
| 2018 Q2 | 1.69 Billion CNY | -11.62% |
| 2018 Q1 | 1.91 Billion CNY | 35.41% |
| 2017 Q2 | 919.48 Million CNY | 16.09% |
| 2017 Q1 | 792.05 Million CNY | -7.08% |
| 2017 FY | 1.41 Billion CNY | 65.78% |
| 2017 Q4 | 1.41 Billion CNY | 33.41% |
| 2017 Q3 | 1.05 Billion CNY | 15.21% |
| 2016 FY | 852.42 Million CNY | -6.19% |
| 2016 Q2 | 1.03 Billion CNY | 8.77% |
| 2016 Q1 | 947.59 Million CNY | 4.28% |
| 2016 Q3 | 989.44 Million CNY | -4.0% |
| 2016 Q4 | 852.42 Million CNY | -13.85% |
| 2015 Q3 | 694.07 Million CNY | 8.33% |
| 2015 Q1 | 555.74 Million CNY | 38.48% |
| 2015 FY | 908.68 Million CNY | 126.43% |
| 2015 Q4 | 908.68 Million CNY | 30.92% |
| 2015 Q2 | 640.73 Million CNY | 15.29% |
| 2014 Q3 | 349.86 Million CNY | -4.4% |
| 2014 FY | 401.31 Million CNY | 144.0% |
| 2014 Q1 | 152.35 Million CNY | -7.37% |
| 2014 Q4 | 401.31 Million CNY | 14.71% |
| 2014 Q2 | 365.95 Million CNY | 140.2% |
| 2013 Q2 | 96.71 Million CNY | 12.72% |
| 2013 FY | 164.47 Million CNY | 53.11% |
| 2013 Q4 | 164.47 Million CNY | 34.55% |
| 2013 Q3 | 122.24 Million CNY | 26.4% |
| 2013 Q1 | 85.79 Million CNY | -20.13% |
| 2012 Q4 | 107.42 Million CNY | 47.38% |
| 2012 FY | 107.42 Million CNY | 80.36% |
| 2012 Q1 | 64.86 Million CNY | 8.9% |
| 2012 Q2 | 71.82 Million CNY | 10.73% |
| 2012 Q3 | 72.88 Million CNY | 1.48% |
| 2011 Q4 | 59.55 Million CNY | 11.88% |
| 2011 Q2 | 43.53 Million CNY | 2.98% |
| 2011 Q1 | 42.27 Million CNY | 30.88% |
| 2011 Q3 | 53.23 Million CNY | 22.28% |
| 2011 FY | 59.55 Million CNY | 84.4% |
| 2010 Q2 | 53.34 Million CNY | 0.0% |
| 2010 FY | 32.29 Million CNY | -40.99% |
| 2010 Q4 | 32.29 Million CNY | 0.0% |
| 2009 FY | 54.73 Million CNY | 46.64% |
| 2008 FY | 37.32 Million CNY | 291.21% |
| 2007 FY | 9.54 Million CNY | 0.0% |